DK3242678T3 - Kombinationspræparater til behandling af cancer eller infektion - Google Patents
Kombinationspræparater til behandling af cancer eller infektion Download PDFInfo
- Publication number
- DK3242678T3 DK3242678T3 DK16700138.7T DK16700138T DK3242678T3 DK 3242678 T3 DK3242678 T3 DK 3242678T3 DK 16700138 T DK16700138 T DK 16700138T DK 3242678 T3 DK3242678 T3 DK 3242678T3
- Authority
- DK
- Denmark
- Prior art keywords
- lag
- virus
- protein
- derivative
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
Claims (17)
1. Kombinationspræparat, der omfatter: (a) LAG-3-protein, eller et derivat deraf, der kan binde til MHC-klasse-II-molekyler, hvor derivatet af LAG-3-protein omfatter en aminosyresekvens, der har mindst 70 % aminosyreidentitet med domæne Dl, og eventuelt domæne D2, af LAG-3-protein, eller hvor derivatet af LAG-3-protein omfatter en aminosyresekvens, der har mindst 70 % aminosyreidentitet med domænerne Dl, D2, D3, og eventuelt D4, af LAG-3-protein; og (b) en programmeret celledødsprotein-1- (PD-1) banehæmmer, hvor PD-1-banehæmmeren omfatter et anti-PD-1-antistof, eller et derivat eller fragment deraf, der bevarer evne til at hæmme binding af PD-1 til PD-L1 og/eller PD-L2, eller hvor PD-1-banehæmmeren omfatter et anti-PD-Ll-antistof, eller et derivat eller fragment deraf, der bevarer evne til at hæmme binding af PD-L1 til PD-1.
2. Farmaceutisk sammensætning, der omfatter: (a) LAG-3-protein, eller et derivat deraf, der kan binde til MHC-klasse-II-molekyler, hvor derivatet af LAG-3-protein omfatter en aminosyresekvens, der har mindst 70 % aminosyreidentitet med domain Dl, og eventuelt domæne D2, af LAG-3-protein, eller hvor derivatet af LAG-3-protein omfatter en aminosyresekvens, der har mindst 70 % aminosyreidentitet med domænerne Dl, D2, D3, og eventuelt D4, af LAG-3-protein; (b) en PD-1-banehæmmer, hvor PD-l-banehæmmeren omfatter et anti-PD-1-antistof, eller et derivat eller fragment deraf, der bevarer evne til at hæmme binding af PD-1 til PD-L1 og/eller PD-L2, eller hvor PD-l-banehæmmeren omfatter et anti-PD-Ll-antistof, eller et derivat eller fragment deraf, der bevarer evne til at hæmme binding af PD-L1 til PD-1; og (c) en farmaceutisk acceptabel bærer, excipiens eller fortynder.
3. Kombinationspræparat ifølge krav 1, eller farmaceutisk sammensætning ifølge krav 2, til coadministration eller sekventiel administration af LAG-3-proteinet, eller et derivat deraf, og PD-1 -banehæmmeren.
4. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst foregående krav, hvor LAG-3-proteinet, eller et derivat deraf, er adskilt fra PD-1- banehæmmeren.
5. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst foregående krav, hvor LAG-3-proteinet, eller et derivat deraf, er til stede i en dosis, der er en molækvivalent af 0,25-30 mg af LAG-3 Ig-fusionsprotein IMP321.
6. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst foregående krav, der omfatter en flerhed af doser af LAG-3-proteinet, eller et derivat deraf og/eller en flerhed af doser af PD-1-banehæmmeren.
7. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst foregående krav, hvor PD-1-banehæmmeren omfatter: et anti-PD-1 -antistof, eller et derivat eller fragment deraf, der bevarer evne til at hæmme binding af PD-1 til PD-L1 og/eller PD-L2, og hvor PD-1-banehæmmeren er pembrolizumab eller nivolumab eller pidilizumab; eller et anti-PD-Ll-antistof, eller et derivat eller fragment deraf, der bevarer evne til at hæmme binding af PD-L1 til PD-1, og hvor PD-1-banehæmmeren er BMS-936559, MED14736, MPDL3280A eller MSB0010718C.
8. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst foregående krav, hvor PD-1-banehæmmeren er til stede ved en dosis, der er op til 50 %, 1-50 %, 1-25 %, eller 1-10 %, af en typisk ordineret dosis af PD-1-banehæmmeren som en monoterapi, eller hvor PD-1-banehæmmeren er til stede ved en dosis, der er 0,1-50 %, 0,1-25 %, 0,1-20 %, 0,1-10 %, <20 %, <10 %, 0,1-<20 %, 0, l-<10 %, 0,01-<20 % eller 0,01-<10 % af en typisk ordineret dosis af PD-1-banehæmmeren som en monoterapi.
9. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst foregående krav, hvor LAG-3-proteinet eller et derivat deraf, og PD-1-banehæmmeren, er til stede i en hvilken som helst af kombinationerne af de doseringsmængder, der vises i nedenstående tabel:
10. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst foregående krav, hvor derivatet af LAG-3-protein omfatter en aminosyresekvens, der har mindst 70 % aminosyreidentitet med domæne Dl, og eventuelt domæne D2, af humant LAG-3-protein, eller hvor derivatet af LAG-3-protein omfatter en aminosyresekvens, der har mindst 70 % aminosyreidentitet med domænerne Dl, D2, D3, og eventuelt D4, af humant LAG-3-protein.
11. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst foregående krav, hvor derivatet af LAG-3-protein er kondenseret til immunoglobulin Fc-sekvensen, fortrinsvis hvor derivatet af LAG-3-protein er det rekombinante opløselige humane LAG-3Ig-fusionsprotein IMP321.
12. Kombinationspræparat eller a farmaceutisk sammensætning ifølge et hvilket som helst af følgende krav til anvendelse som et medikament.
13. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst af kravene 1 til 11 til anvendelse i forebyggelse, behandling eller bedring af cancer.
14. Kombinationspræparat eller farmaceutisk sammensætning til anvendelse ifølge krav 13, hvor canceren er en PD-L1-positiv eller en PD-L2-positiv cancer, eller hvor canceren er hud-, lunge- (navnlig pladeepitel- eller ikke-pladeepitel- ikke-småcellet lungekarcinom, NSCLC), ovarie-, nyre-, colon-, kolorektal-, bryst-, gastrisk, øsofagus-, pankreas-, blære-, urotelial- eller levercancer, eller et melanom (for eksempel, metastatisk malignt melanom), en prostatacancer (for eksempel hormonrefraktært prostataadenokarcinom), cancer i hoved eller hals (for eksempel pladeepitelkarcinom i hoved og hals), en cervixcancer, en thyroideacancer, et glioblastom, et gliom, leukæmi, et lymfom (for eksempel, et B-cellelymfom), en binyrecancer, en aids-associeret cancer, et alveolært bløddelssarkom, en astrocytisk tumor, knoglecancer, en cancer i hjerne og rygmarv, en metastatisk hjernetumor, en karotidlegemetumor, et chondrosarkom, et chordom, et kromofobt nyrecellekarcinom, et spytkirtelkarcinom, kutant benignt fibrøst histiocytom, en desmoplastisk småcellet rund tumor, et ependymom, en Ewings tumor, et ekstraskeletalt myksoidt chondrosarkom, fibrogenesis imperfecta ossium, fibrøst knogledysplasi, en gæIdeblære- eller galdevejscancer, en gestational trofoblastisk sygdom, en kimcelletumor, en hæmatologisk malignitet, et hepatocellulært karcinom, en øcelletumor, et Kaposis sarkom, en nyrecancer, et lipom/en benign lipomatøs tumor, et liposarkom/en malign lipomatøs tumor, et medulloblastom, et meningiom, et Merkelcellekarcinom, en multipel endokrin neoplasi, et multiplet myelom, et myelodysplasisyndrom, et neuroblastom, en neuroendokrin tumor, et papillært thyroideakarcinom, et parathyroideatumor, en pædiatrisk cancer, en perifer nerveskedetumor, et phæochromocytom, en hypofysetumor, en prostatacancer, et posteriori uvealt melanom, en sjælden hæmatologisk forstyrrelse, en metastatisk nyrecancer, en rhabdoid tumor, et rhabdomysarkom, et sarkom, et blødvævssarkom, en pladeepitelcancer, en mavecancer, et synovialsarkom, en testiscancer, et thymuskarcinom, et thymom, en metastatisk thyreoideacancer eller en uteruscancer.
15. Kombinationspræparat eller farmaceutisk sammensætning ifølge et hvilket som helst af kravene 1 til 11 til anvendelse i forebyggelse, behandling eller bedring af en infektion.
16. Kombinationspræparat til anvendelse ifølge krav 15, hvor infektionen er en kronisk eller vedvarende infektion.
17. Kombinationspræparat til anvendelse ifølge krav 15 eller 16, hvor infektionen er en virus-, bakterie-, svampe- eller protozoinfektion, fortrinsvis hvor virusinfektionen er forårsaget af et adenovirus, et adenoassocieret virus, et B-virus (macacine herpesvirus I), et BK-virus, et bunyavirus, et chikungunya-virus, et cocksackie-virus, et coronavirus, et cytomegalovirus, et østligt hesteencephalitis-virus, et ebolavirus, et enterovirus, et Epstein-Barr-virus, et hantavirus, et hepatitis A-virus, et hepatitis B-virus, et hepatitis C-virus, et hepatitis D-virus, et hepatitis E-virus, et herpesvirus, et herpes simplex virus 1, et herpes simplex virus 2, et humant spumavirus, et humant herpesvirus 3, et humant herpesvirus 5, et humant herpesvirus 6, et humant herpesvirus 7, et humant immundefektvirus, et humant papillomavirus, et humant β-lymfotrofisk virus, et humant T-celle-leukæmivirus I, et humant T-celle-leukæmivirus II, et influenzavirus, et JC-virus, et JEV, et Kaposis sarkom-associeret herpesvirus, et Lassa-virus, et lymfocytisk choriomeningitisvirus, et Marburg-virus, et mæslingevirus, et fåresygevirus, et Nipah-virus, et norovirus, et Norwalk-virus, et orthoreovirus, et parainfluenzavirus, et parvovirus, et poliovirus, et rabiesvirus, et reovirus, et respiratorisk syncytialvirus, rhinovirus, et Rift Valley-febervirus, et rotavirus, rubellavirus, et koppervirus, et St Louis encephalitisvirus, et variola major virus, et variola minor virus, et vericella-zoster-virus, et vestnilvirus, et vestligt hesteencephalitis-virus eller et gul febervirus, eller hvor bakterieinfektionen er forårsaget af Escherichia coli, Clostridium difficile, Salmonella thyphimurium, Pseudomonas aeruginosa, Vibrio cholerae, Neisseria gonorrhoeae, Helicobacter pylori, Hemophilus influenzae, Shigella dysenteriae, Staphylococcus aureus, Mycobacterium tuberculosis, Streptococcus pneumonia eller Chlamydia trachomatis, eller hvor svampeinfektionen er forårsaget af Candida, Aspergillus, Cryptococcus, Coccidioides, Histoplasma, Pneumocystis, eller Stachybotrys, eller hvor protozoinfektionen er forårsaget af Amoebozoa, Excavata, Chromalveolata, Entamoeba, Plasmodium, Giardia, Trypanosoma, Coccidia, Besnoitia, Dicrocoelium eller Leishmania.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1500374.2A GB201500374D0 (en) | 2015-01-09 | 2015-01-09 | Combined preparations for the treatment of cancer |
PCT/EP2016/050321 WO2016110593A1 (en) | 2015-01-09 | 2016-01-08 | Combined preparations for the treatment of cancer or infection |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3242678T3 true DK3242678T3 (da) | 2019-03-11 |
Family
ID=52597438
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18208378.2T DK3473263T3 (da) | 2015-01-09 | 2016-01-08 | Kombinerede præparater til behandling af kræft |
DK16700138.7T DK3242678T3 (da) | 2015-01-09 | 2016-01-08 | Kombinationspræparater til behandling af cancer eller infektion |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18208378.2T DK3473263T3 (da) | 2015-01-09 | 2016-01-08 | Kombinerede præparater til behandling af kræft |
Country Status (22)
Country | Link |
---|---|
US (5) | US10874713B2 (da) |
EP (3) | EP3473263B1 (da) |
JP (4) | JP7116547B2 (da) |
KR (1) | KR20170120104A (da) |
CN (2) | CN114146161A (da) |
AU (3) | AU2016205983B2 (da) |
BR (1) | BR112017014742A2 (da) |
CA (1) | CA2973044A1 (da) |
CY (1) | CY1124462T1 (da) |
DK (2) | DK3473263T3 (da) |
ES (2) | ES2704272T3 (da) |
GB (1) | GB201500374D0 (da) |
HR (1) | HRP20211346T1 (da) |
HU (1) | HUE055433T2 (da) |
IL (1) | IL253243A0 (da) |
LT (1) | LT3473263T (da) |
MX (2) | MX2017009003A (da) |
PL (2) | PL3242678T3 (da) |
PT (2) | PT3473263T (da) |
SI (1) | SI3473263T1 (da) |
TR (1) | TR201901077T4 (da) |
WO (1) | WO2016110593A1 (da) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
LT3081576T (lt) | 2013-12-12 | 2019-10-25 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antikūnas, antigeną surišantis jo fragmentas ir jų medicininis pritaikomumas |
GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
KR20180040138A (ko) | 2015-07-13 | 2018-04-19 | 싸이톰스 테라퓨틱스, 인크. | 항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법 |
HUE065242T2 (hu) | 2017-05-30 | 2024-05-28 | Bristol Myers Squibb Co | LAG-3-pozitív tumorok kezelése |
CA3065304A1 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody |
CN112236456B (zh) * | 2018-03-20 | 2023-12-22 | 上海药明生物技术有限公司 | 新型双特异性pd-1/lag-3抗体分子 |
EP3826660A1 (en) * | 2018-07-26 | 2021-06-02 | Bristol-Myers Squibb Company | Lag-3 combination therapy for the treatment of cancer |
JP2022534005A (ja) * | 2019-05-22 | 2022-07-27 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | 薬学的組合せ |
KR20220054282A (ko) * | 2019-06-14 | 2022-05-02 | 지 테크 바이오 엘엘씨 | 활성화 림프구성 세포 및 암 및 감염 질환을 치료하기 위해 그를 사용하는 방법 |
CN110938691B (zh) * | 2019-12-03 | 2023-07-07 | 兰州大学 | 人dus4l基因的用途及相关产品 |
CN110950966B (zh) * | 2019-12-13 | 2020-12-11 | 启辰生生物科技(珠海)有限公司 | 融合蛋白、编码核酸和细胞及用途 |
GB202108718D0 (en) | 2021-06-18 | 2021-08-04 | Immutep Sas | Triple combination therapy |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5078996A (en) | 1985-08-16 | 1992-01-07 | Immunex Corporation | Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor |
US5098702A (en) | 1986-04-09 | 1992-03-24 | Cetus Corporation | Combination therapy using interleukin-2 and tumor necrosis factor |
CA1341281C (en) | 1986-07-09 | 2001-08-07 | Hubert J.P. Schoemaker | Immunotherapy of tumor with monoclonal antibody against the 17-1a antigen |
US5785973A (en) | 1988-02-01 | 1998-07-28 | Praxis Biologics, Inc. | Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines |
EP0432216A1 (en) | 1988-09-01 | 1991-06-19 | Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
US5665577A (en) | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
EP0628570A1 (en) | 1989-02-17 | 1994-12-14 | Chiron Mimotopes Pty. Ltd. | Method for the use and synthesis of peptides |
US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
JP3051411B2 (ja) | 1989-03-14 | 2000-06-12 | 持田製薬株式会社 | 新規dnaならびにそれを含有する発現プラスミド |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
US5976877A (en) | 1990-01-08 | 1999-11-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses |
FR2656800B1 (fr) | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
US7294712B2 (en) | 1990-06-04 | 2007-11-13 | Aventis Pharma S.A. | Nucleotide sequences coding for variable regions of β chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses |
US5981276A (en) | 1990-06-20 | 1999-11-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
DK0551401T3 (da) | 1990-09-14 | 1996-01-22 | Univ Texas | Fremgangsmåde og præparater til genterapi og potensering af antitumor-immunitet |
JP3459268B2 (ja) | 1990-09-17 | 2003-10-20 | 中外製薬株式会社 | 抗癌剤 |
AU660660B2 (en) | 1991-02-08 | 1995-07-06 | Roussel-Uclaf | Nucleotide sequences coding for alpha chain variable regions in human lymphocyte receptors and applications thereof |
US6596536B1 (en) | 1991-02-08 | 2003-07-22 | Aventis Pharma S.A. | Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses |
IE920447A1 (en) | 1991-02-12 | 1992-08-12 | Roussel Uclaf | NUCLEOTIDE SEQUENCES CODING FOR ß-CHAIN VARIABLE REGIONS OF¹HUMAN T-LYMPHOCYTE RECEPTORS, CORRESPONDING PEPTIDE SEGMENTS¹AND DIAGNOSTIC AND THERAPEUTIC APPLICATIONS |
US5637483A (en) | 1991-10-04 | 1997-06-10 | Whitehead Institute For Biomedical Research | Irradiated tumor cell vaccine engineered to express GM-CSF |
US5904920A (en) | 1991-10-04 | 1999-05-18 | Whitehead Institute For Biomedical Research | Regulation of systemic immune responses utilizing cytokines and antigens |
US6506604B2 (en) | 1993-06-11 | 2003-01-14 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
ATE352617T1 (de) | 1994-05-06 | 2007-02-15 | Roussy Inst Gustave | Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper |
US5872005A (en) | 1994-11-03 | 1999-02-16 | Cell Genesys Inc. | Packaging cell lines for adeno-associated viral vectors |
US6040183A (en) | 1995-06-07 | 2000-03-21 | University Of North Carloina At Chapel Hill | Helper virus-free AAV production |
US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
EP0831880A4 (en) | 1995-06-07 | 2004-12-01 | Imclone Systems Inc | ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH |
US6033674A (en) | 1995-12-28 | 2000-03-07 | Johns Hopkins University School Of Medicine | Method of treating cancer with a tumor cell line having modified cytokine expression |
US5840839A (en) | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
US6277368B1 (en) | 1996-07-25 | 2001-08-21 | The Regents Of The University Of California | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
WO1998023741A1 (fr) | 1996-11-28 | 1998-06-04 | Institut Gustave Roussy | Mutants de la proteine lag-3, leur expression et utilisation |
EA003772B1 (ru) | 1996-11-29 | 2003-08-28 | Апплайд Резеч Системз Арс Холдинг Н.В. | Средство для обеспечения защиты трансплантата от отторжения иммунной системой хозяина на основе штамма генетически сконструированных эукариотических клеток, содержащих днк, кодирующую трансмембранный белок lag-3 |
CA2287478C (en) | 1997-04-14 | 2007-06-19 | Richard J. Samulski | Methods for increasing the efficiency of recombinant aav product |
EP0893507A1 (en) * | 1997-07-25 | 1999-01-27 | Institut Gustave Roussy | Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment |
US6037177A (en) | 1997-08-08 | 2000-03-14 | Cell Genesys, Inc. | Method for increasing the efficiency of recombinant AAV production |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
US6464973B1 (en) | 1998-02-02 | 2002-10-15 | Johns Hopkins University, School Of Medicine | Universal GM-CSF expressing bystander human K562 cell line |
FR2777890B1 (fr) | 1998-04-22 | 2000-12-29 | Roussy Inst Gustave | Composes peptidiques d'hsp70 utiles dans l'immunotherapie du cancer |
WO2000072686A1 (en) | 1999-06-02 | 2000-12-07 | Cell Genesys, Inc. | Regulation of systemic immune responses utilizing cytokines and antigens |
WO2000077201A1 (en) | 1999-06-15 | 2000-12-21 | Astrazeneca Ab | Livin; inhibitor-of-apoptosis protein-3 (iap-3) |
FR2795415B1 (fr) | 1999-06-28 | 2003-09-05 | Roussy Inst Gustave | Compose peptidique derive d'une orf decalee du gene ice |
AT409086B (de) | 1999-11-16 | 2002-05-27 | Igeneon Krebs Immuntherapie | Neue verwendung von antikörpern als impfstoffe |
CA2406949A1 (fr) | 2000-04-26 | 2001-11-01 | Roger Kravtzoff | Utilisation de vecteurs particulaires dans l'immunomodulation |
US7919467B2 (en) | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
EP1295895B1 (en) | 2001-09-19 | 2011-08-10 | Institut Gustave Roussy | Peptides and proteins binding to glu-pro motifs, therapeutical compositions containing the same and applications thereof |
CA2752140A1 (en) | 2002-05-17 | 2003-11-27 | Celgene Corporation | Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-1-yl)-piperidine-2,6-dione for treatment and management of renal cancer |
ES2654064T3 (es) | 2002-07-03 | 2024-03-13 | Ono Pharmaceutical Co | Composiciones inmunopotenciadoras que comprenden anticuerpos anti-PD-L1 |
US7439042B2 (en) | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
US20040197312A1 (en) | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
KR20060123138A (ko) | 2003-10-10 | 2006-12-01 | 파우더젝트 백신, 인코포레이티드 | 방법 |
FR2868781B1 (fr) | 2004-04-13 | 2008-02-22 | Immutep | Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations |
JP2006124383A (ja) | 2004-09-30 | 2006-05-18 | Kobayashi Pharmaceut Co Ltd | 樹状細胞活性化剤 |
JP2006141346A (ja) | 2004-11-24 | 2006-06-08 | Kobayashi Pharmaceut Co Ltd | 樹状細胞活性化剤 |
US20070231298A1 (en) | 2006-03-31 | 2007-10-04 | Cell Genesys, Inc. | Cytokine-expressing cancer immunotherapy combinations |
US7919079B2 (en) | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 pd-1에 대한 항체 |
US8425897B2 (en) | 2007-08-30 | 2013-04-23 | Immutep S.A. | Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use |
EP2044949A1 (en) * | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
JP6320756B2 (ja) | 2010-12-06 | 2018-05-09 | キュア キャンサー ワールドワイド エルエルシー | 癌を治療するための化学および免疫療法を用いた癌細胞の代謝標的法 |
PL2691112T3 (pl) | 2011-03-31 | 2018-09-28 | Merck Sharp & Dohme Corp. | Stabilne preparaty przeciwciał przeciw ludzkiemu receptorowi programowanej śmierci pd-1 i terapie powiązane |
JP2015512616A (ja) * | 2012-02-01 | 2015-04-30 | コンピュゲン エルティーディー. | C1orf32抗体およびがんの治療のためのその使用 |
BR122022015975B1 (pt) | 2012-05-15 | 2024-01-02 | Bristol-Myers Squibb Company | Anticorpos monoclonais, kit para o tratamento de um indivíduo afligido com um câncer, processo para medir pd-l1 membranoso em células tumorais isoladas e uso do anticorpo ou uma porção que se liga ao antígeno do mesmo |
US9890215B2 (en) | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
WO2014194293A1 (en) | 2013-05-30 | 2014-12-04 | Amplimmune, Inc. | Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof |
BR122023024195A2 (pt) * | 2013-09-20 | 2023-12-26 | Bristol-Myers Squibb Company | Usos de anticorpos anti-lag-3 e anticorpos anti-pd-1 |
GB201322626D0 (en) | 2013-12-19 | 2014-02-05 | Immutep S A | Combined preparations for the treatment of cancer |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
WO2015131176A1 (en) | 2014-02-28 | 2015-09-03 | Podack Eckhard R | Compositions, methods, and kits for treatment of cancer |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
GB201500374D0 (en) | 2015-01-09 | 2015-02-25 | Immutep S A | Combined preparations for the treatment of cancer |
-
2015
- 2015-01-09 GB GBGB1500374.2A patent/GB201500374D0/en not_active Ceased
-
2016
- 2016-01-08 KR KR1020177022072A patent/KR20170120104A/ko active IP Right Grant
- 2016-01-08 EP EP18208378.2A patent/EP3473263B1/en active Active
- 2016-01-08 CN CN202111344452.8A patent/CN114146161A/zh active Pending
- 2016-01-08 DK DK18208378.2T patent/DK3473263T3/da active
- 2016-01-08 CA CA2973044A patent/CA2973044A1/en active Pending
- 2016-01-08 ES ES16700138T patent/ES2704272T3/es active Active
- 2016-01-08 MX MX2017009003A patent/MX2017009003A/es unknown
- 2016-01-08 PL PL16700138T patent/PL3242678T3/pl unknown
- 2016-01-08 TR TR2019/01077T patent/TR201901077T4/tr unknown
- 2016-01-08 ES ES18208378T patent/ES2885901T3/es active Active
- 2016-01-08 LT LTEP18208378.2T patent/LT3473263T/lt unknown
- 2016-01-08 EP EP21173154.2A patent/EP3943099A1/en active Pending
- 2016-01-08 WO PCT/EP2016/050321 patent/WO2016110593A1/en active Application Filing
- 2016-01-08 HU HUE18208378A patent/HUE055433T2/hu unknown
- 2016-01-08 DK DK16700138.7T patent/DK3242678T3/da active
- 2016-01-08 EP EP16700138.7A patent/EP3242678B1/en active Active
- 2016-01-08 PT PT182083782T patent/PT3473263T/pt unknown
- 2016-01-08 MX MX2021000299A patent/MX2021000299A/es unknown
- 2016-01-08 SI SI201631321T patent/SI3473263T1/sl unknown
- 2016-01-08 CN CN201680005401.3A patent/CN107249619B/zh active Active
- 2016-01-08 JP JP2017536009A patent/JP7116547B2/ja active Active
- 2016-01-08 US US15/542,466 patent/US10874713B2/en active Active
- 2016-01-08 PL PL18208378T patent/PL3473263T3/pl unknown
- 2016-01-08 PT PT16700138T patent/PT3242678T/pt unknown
- 2016-01-08 AU AU2016205983A patent/AU2016205983B2/en active Active
- 2016-01-08 BR BR112017014742A patent/BR112017014742A2/pt active Search and Examination
-
2017
- 2017-06-29 IL IL253243A patent/IL253243A0/en unknown
-
2020
- 2020-01-03 US US16/733,829 patent/US10940181B2/en active Active
- 2020-02-07 JP JP2020019441A patent/JP2020073594A/ja active Pending
- 2020-10-16 US US17/072,612 patent/US11684654B2/en active Active
-
2021
- 2021-08-24 HR HRP20211346TT patent/HRP20211346T1/hr unknown
- 2021-08-30 CY CY20211100764T patent/CY1124462T1/el unknown
-
2022
- 2022-01-11 AU AU2022200133A patent/AU2022200133A1/en active Pending
- 2022-06-16 JP JP2022097184A patent/JP2022118119A/ja active Pending
- 2022-09-06 US US17/929,888 patent/US20230074746A1/en active Pending
-
2023
- 2023-05-05 US US18/312,626 patent/US20230330182A1/en active Pending
- 2023-12-07 JP JP2023206838A patent/JP2024015265A/ja active Pending
-
2024
- 2024-06-19 AU AU2024204196A patent/AU2024204196A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11684654B2 (en) | Combined preparations for the treatment of cancer or infection | |
Andrews et al. | LAG 3 (CD 223) as a cancer immunotherapy target | |
Jacobs et al. | Immune checkpoint modulation in colorectal cancer: what’s new and what to expect | |
Piconese et al. | OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection | |
KR20170003575A (ko) | 비-소세포 폐암을 치료하기 위한 항-b7-h1 및 항-ctla-4 항체 | |
EP3091999B1 (en) | Improved cell compositions and methods for cancer therapy | |
US20200182858A1 (en) | Methods of treatment with cd80 extracellular domain polypeptides | |
EP3052131A1 (en) | Methods for treating cancer in patients with elevated levels of bim | |
KR20210093950A (ko) | Il-7 단백질 및 면역 관문 저해제의 조합으로 종양을 치료하는 방법 | |
Wong et al. | Future of immunotherapy in pancreas cancer and the trials, tribulations and successes thus far | |
RU2777945C2 (ru) | Комбинированные препараты для лечения рака или инфекции | |
MacKenzie | New therapeutics that treat rheumatoid arthritis by blocking T-cell activation | |
Shen et al. | Checkpoint inhibition and CAR T cells for the Treatment of Glioblastoma | |
US20230023174A1 (en) | Cd80 extracellular domain fc fusion protein regimens |